Allergen-specific lung-resident Tregs in asthma: Targetable suppressors of resident memory Th2 cells
哮喘中过敏原特异性肺常驻 Tregs:常驻记忆 Th2 细胞的靶向抑制因子
基本信息
- 批准号:10418189
- 负责人:
- 金额:$ 60.02万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-02-04 至 2027-01-31
- 项目状态:未结题
- 来源:
- 关键词:Adoptive TransferAllergensAllergicAllergic inflammationAnatomyAntigensAsthmaBone MarrowCCL1 geneCCL8 geneCCR8 geneCD4 Positive T LymphocytesCXCR6 geneCellsChronic DiseaseEffector CellExhibitsExtrinsic asthmaFOXP3 geneFailureFlow CytometryFrequenciesGenerationsGenetic TranscriptionGoalsHumanImmune responseImmune systemImmunohistochemistryImmunosuppressive AgentsIn VitroIndividualInflammationInhalationLeadLigandsLocationLungMUC5AC geneMaintenanceMediatingMemoryMetaplasiaModelingMucinsMucous body substanceMusPatternPeptidesPhenotypePlayPopulationPositioning AttributePrevalenceProductionProliferatingPulmonary InflammationPyroglyphidaeRegulatory T-LymphocyteReporterResidenciesResolutionRoleSpecificitySurfaceSystemT memory cellTestingTh2 CellsTherapeuticTimeTissuesTransgenic OrganismsUp-Regulationairborne allergenairway hyperresponsivenessairway immune responseairway inflammationallergic responseasthma modelchemokinechemokine receptorchronic inflammatory diseasecost estimatecytokineenvironmental allergeneosinophilexperimental studynovel therapeutic interventionprogramsresponsesingle-cell RNA sequencingtranscriptome sequencingtreatment strategy
项目摘要
Asthma is one of the most common chronic diseases and it is still on the rise with a prevalence of ~8% of the
U.S. population and an estimated cost of $82 billion/year. New therapeutic approaches are needed that offer the
potential for a long-lasting cure. Allergic asthma is the most common endotype and is thought to be driven in
large part by a type 2 airway immune response to inhaled allergens. Foxp3+ regulatory T cells (Tregs) are potent
suppressors of immune responses and are an attractive target to treat allergic asthma. The CD4+ T helper type
2 (Th2)-mediated response to environmental allergens that drives allergic asthma is thought to be due to an
imbalance between allergen-specific effector and regulatory responses. Recent studies by us and others have
demonstrated that resident memory (Trm) Th2 cells that reside in the lung are key effector cells that drive many
of the features of allergic asthma. Th2-Trm cells proliferate near airways following allergen challenge and are
responsible for inducing mucus metaplasia, airway hyperresponsiveness, and airway eosinophil activation. While
memory T cells were believed to continually re-circulate within the host, it has recently become clear that Trm
remain anatomically positioned to initiate antigen-specific immune responses at barrier surfaces. In preliminary
studies, we have now found that allergen-specific Tregs also reside in the lung following aeroallergen
sensitization and are the key cell that suppresses the Th2-Trm response. This has led us to the central
hypothesis of this proposal that resident (r) Treg suppression of Th2-Trm is key to regulating the allergic asthma
phenotype. Th2-Trm exhibit a distinct transcriptional program that includes the upregulation of the chemokine
receptors CCR8 and CXCR6. In preliminary studies, we have found rTregs in the lung also upregulate CCR8
and CXCR6 during a type 2 response. This has led us to hypothesize that the CCR8 and CXCR6 chemokine
systems play roles in the tissue residency programs of Tregs and their ability to be juxtaposed to Th2-Trm around
the airways. The central hypothesis of this proposal will also be explored in humans with allergic asthma. Our
group has investigated the response to bronchoscopic segmental allergen challenge in humans with allergic
asthma (AA) and allergic non-asthmatic controls (ANA). We found increased airway type 2 cytokine production,
total mucin, and mucin MUC5AC in response to allergen in AA compared to ANA subjects. These findings
suggest that differences in the activation of Th2-Trm within the airways may be critical for allergen-sensitized
individuals to develop the asthma phenotype. We will test the hypothesis that differences in relative frequency,
phenotype and/or TCR specificities of rTregs in the lung underly the differences in the response to aeroallergen
in ANA and AA subjects. Specifically, we propose to: (1) Further define the role of lung rTregs in suppressing
Th2-Trm; (2) Determine the role of the CCR8 and CXCR6 chemokine systems in the tissue residency program
positioning and function of rTregs in the allergic lung; and (3) Extend these studies to humans by comparing the
numbers, phenotype and TCR specificities of rTregs in AA and ANA subjects.
哮喘是最常见的慢性疾病之一,其患病率仍在上升,约占全球人口的8%
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANDREW D LUSTER其他文献
ANDREW D LUSTER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANDREW D LUSTER', 18)}}的其他基金
Allergen-specific lung-resident Tregs in asthma: Targetable suppressors of resident memory Th2 cells
哮喘中过敏原特异性肺常驻 Tregs:常驻记忆 Th2 细胞的靶向抑制因子
- 批准号:
10563192 - 财政年份:2022
- 资助金额:
$ 60.02万 - 项目类别:
Features of Broad T Cell Coronavirus Immunity
广泛 T 细胞冠状病毒免疫的特点
- 批准号:
10842889 - 财政年份:2021
- 资助金额:
$ 60.02万 - 项目类别:
Features of Broad T Cell Coronavirus Immunity
广泛 T 细胞冠状病毒免疫的特点
- 批准号:
10328120 - 财政年份:2021
- 资助金额:
$ 60.02万 - 项目类别:
The CXCR3 Chemokine System in Cancer Immunotherapy
癌症免疫治疗中的 CXCR3 趋化因子系统
- 批准号:
10053710 - 财政年份:2016
- 资助金额:
$ 60.02万 - 项目类别:
2014 Chemotactic Cytokines Gordon Research Conference and Gordon Research Seminar
2014年趋化细胞因子戈登研究大会暨戈登研究研讨会
- 批准号:
8708388 - 财政年份:2014
- 资助金额:
$ 60.02万 - 项目类别:
2012 Chemotactic Cytokines Gordon Research Conference & Gordon Research Seminar
2012年趋化细胞因子戈登研究会议
- 批准号:
8307657 - 财政年份:2012
- 资助金额:
$ 60.02万 - 项目类别:
Linking allergen-specific T cell effector and regulatory responses to asthma
将过敏原特异性 T 细胞效应器与哮喘调节反应联系起来
- 批准号:
8196484 - 财政年份:2011
- 资助金额:
$ 60.02万 - 项目类别:
T cell effector and regulatory mechanisms in asthma and food allergy
哮喘和食物过敏中的 T 细胞效应和调节机制
- 批准号:
8707948 - 财政年份:2011
- 资助金额:
$ 60.02万 - 项目类别:
T cell effector and regulatory mechanisms in asthma and food allergy
哮喘和食物过敏中的 T 细胞效应和调节机制
- 批准号:
8165321 - 财政年份:2011
- 资助金额:
$ 60.02万 - 项目类别:
相似海外基金
Measurement of serum IgE and identification of allergens in seafood allergic patients
海鲜过敏患者血清IgE测定及过敏原鉴定
- 批准号:
21K13490 - 财政年份:2021
- 资助金额:
$ 60.02万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mechanisms of augmentation of contact allergic reactions by irritants and contact allergens
刺激物和接触性过敏原增强接触性过敏反应的机制
- 批准号:
335858052 - 财政年份:2017
- 资助金额:
$ 60.02万 - 项目类别:
Research Grants
Elucidation of conformational epitopes of peanut allergens essential for allergic reactions
阐明过敏反应所必需的花生过敏原的构象表位
- 批准号:
8970024 - 财政年份:2015
- 资助金额:
$ 60.02万 - 项目类别:
Environmental allergens affect the function of allergic inflammatory cells
环境过敏原影响过敏性炎症细胞的功能
- 批准号:
26860758 - 财政年份:2014
- 资助金额:
$ 60.02万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Effects of allergens on dendritic cell function in allergic asthma
过敏原对过敏性哮喘树突状细胞功能的影响
- 批准号:
nhmrc : 303161 - 财政年份:2004
- 资助金额:
$ 60.02万 - 项目类别:
NHMRC Project Grants
IImmune Tolerance Network: Airborne Allergens and Allergic Rhintitis
II免疫耐受网络:空气中的过敏原和过敏性鼻炎
- 批准号:
8348615 - 财政年份:2001
- 资助金额:
$ 60.02万 - 项目类别:
IImmune Tolerance Network: Airborne Allergens and Allergic Rhintitis
II免疫耐受网络:空气中的过敏原和过敏性鼻炎
- 批准号:
8522031 - 财政年份:2001
- 资助金额:
$ 60.02万 - 项目类别:
IImmune Tolerance Network: Airborne Allergens and Allergic Rhintitis
II免疫耐受网络:空气中的过敏原和过敏性鼻炎
- 批准号:
8730013 - 财政年份:2001
- 资助金额:
$ 60.02万 - 项目类别:
ASPERGILLUS ALLERGENS AND ALLERGIC ASPERGILLOSIS
曲霉过敏原和过敏性曲霉病
- 批准号:
6137243 - 财政年份:1998
- 资助金额:
$ 60.02万 - 项目类别:
ASPERGILLUS ALLERGENS AND ALLERGIC ASPERGILLOSIS
曲霉过敏原和过敏性曲霉病
- 批准号:
2462172 - 财政年份:1998
- 资助金额:
$ 60.02万 - 项目类别:














{{item.name}}会员




